Aberdeen Group
BCRX icon

Aberdeen Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Aberdeen Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48M Buy
5,040,670
+4,127,077
+452% +$32.1M 0.08% 224
2025
Q4 		$7.13M Buy
+913,593
New +$6.6M 0.01% 661
2024
Q1 		– Sell
-504,528
Closed -$3.02M – 952
2023
Q4 		$3.02M Buy
+504,528
New +$2.92M 0.01% 742

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Aberdeen Group's BCRX Position: Q1 2026 in Review

Aberdeen Group increased its BioCryst Pharmaceuticals (BCRX) stake by 452% in Q1 2026, buying an estimated $32.1M and bringing the position to 5,040,670 shares worth $48M. The position accounts for 0.08% of the portfolio, ranked #224.

Aberdeen Group first reported a position in BCRX in Q4 2023 and has held it in 3 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Aberdeen Group held 5,040,670 shares of BioCryst Pharmaceuticals worth $48M as of Q1 2026.
  • Aberdeen Group bought 4,127,077 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $32.1M.
  • BioCryst Pharmaceuticals made up 0.08% of Aberdeen Group's portfolio in Q1 2026, its #224 holding.
  • Aberdeen Group first reported a position in BioCryst Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.